GRFS News and Press, Grifols S.A. From 11/16/20

Soros's 13F portfolio value decreased from $4.48B to $4.08B this quarter. The number of positions decreased from 141 to 132. Soros added Palantir Technologies and Unity Software, while reducing T-Mobile US. Also, most of their recent additions in Financials were either reduced or elim...

Grifols partners with TRC Healthcare to streamline intravenous compounding education -- The integration of Grifols PharmacyKeeper and clinical education resources from TRC Healthcare will help pharmacy leaders by delivering the most current and relevant evidence-based education ...

Oligopoly of four companies that control more than 80% of the plasma business. Secular growth trend for population aging. After a bad 1H20, we expect a recovery in the 2H20. The stock is trading EUR 15.76, but we think it is worth more than EUR 26.38, representing upside poten...

The Spanish market has gotten crushed with an uptick in COVID-19 deaths. Grifols stock is about where it was when I visited headquarters three years ago. Morgan Stanley thinks things will be quiet for a while until COVID-19 passes. Blood plasma producers should do well even in...

Grifols S.A. (GRFS) had declared $0.2027/share dividend.Payable Nov. 9; for shareholders of record Nov. 2; ex-div Oct. 30.See GRFS Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Grifols S.A. goes ex-dividend tomorrow

SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Build...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes On Stimulus Developments AgainInvestors are still largely focused on new twists and turns with stimulus efforts in the U.S. Last night, President Dona...

Grifols (GRFS) has started a randomized clinical trial to test its safety, efficacy and tolerability of its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19.This medicine provides a high and consistent concentration of purified neutralizing antibodies and could be used...

Takeda (TAK) is among a group of companies who have begun testing an experimental COVID-19 treatment derived from convalescent plasma of those recovered from the disease. The study, funded by the National Institute of Allergy and Infectious Diseases, will compare the new drug in combination w...

Investment Thesis CSL Limited ( CSLLY ) has yet to fully recover from the plasma shortages experienced during the lockdowns. The impact on production is likely to materialize just as elective surgeries resume. The influenza vaccine sales can pick up the slack as fears mount over a flu outb...